Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

NCT ID: NCT04420533

Last Updated: 2022-10-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-05
• Study Completion Date: 2022-08-31

Brief Summary

The objective of this study is to evaluate and compare the therapeutic effects on OAB symptoms, and sexual functions, in terms of erectile function and ejaculatory function, in sexually active OAB male treated with behavior therapy or behavior therapy plus Mirabegron (50 mg).

Detailed Description

Overactive bladder (OAB) syndrome is a subset of storage-predominant lower urinary tract symptoms (LUTS) and has a significant impact on quality of life. Men with OAB generally experience a reduced quality of life, which may include a negative impact on sexual function. A previous study revealed that OAB is associated with erectile dysfunction (ED; prevalence odds ratio, 1.5; 95% confidence interval, 1.1-2.2) to a level comparable with that of hypertension or diabetes, both of which are known risk factors for ED. Furthermore, men with OAB were nine and seven times more likely to report diminished sexual enjoyment and decreased sexual activity, respectively, due to urinary symptoms than men without urinary symptoms.

Behavior therapies are designed as first- line treatment for the treatment of OAB with or without concomitant medication. Mirabegron, a selective β3 adrenoceptor agonist, is indicated for the treatment of OAB. Earlier research studying the role and distribution of β3-adrenoreceptors revealed that the receptors exert other physiological functions such as lipolysis and are present not only in adipose tissue but also in human gall bladder, colon, prostate, skeletal muscles and corpus cavernosum (CC) smooth muscles. It was found that activation by a selective experimental β3-receptor agonist, BRL 37344, elicited relaxation of human CC smooth muscle via a cGMP-dependent but NO-independent mechanism, leading to observable β3-receptor-mediated vasorelaxant tone of CC. The potential effect of β3-receptor agonism at human CC mediated by highly selective mirabegron in both human CC and rat CC that mirabegron markedly relaxed isolated CC strips by activating β3-adrenoceptors localized in cavernosal smooth muscle cells, independently of the NO-cGMP pathway. Recently, intra-cavernosal injection of mirabegron improved erectile function and neurogenic relaxation of corpus cavernosum in diabetic rats.

These early results have spurred research interest in mirabegron-induced CC relaxation and encouraged further clinical studies observing and evaluating the effect of mirabegron on male sexual function. Researchers at Johns Hopkins University has recently completed recruitment of a phase 1 interventional trial (NCT02916693) that aimed to address the hypothesis that activation of β3-adrenoceptors by mirabegron offers an alternative pharmacologic pathway for the treatment of erectile dysfunction. A preliminary small-scale prospective interventional study including 128 male LUTS patients treated with mirabegron 50 mg, 34 of whom had diagnosis of OAB and were sexually active, showed that mirabegron usage did not improve erectile function, as evaluated by International Index of Erectile Function (IIEF-5 4.9% decrease at 4-week; p = 0.106, and 9.1% decrease at 12-week follow-up; p = 0.077). However, the IIEF-5 was significantly decreased in the higher baseline IIEF-5 (≥17) group (11.7% decrease; p = 0.044), noncoronary artery disease (13.2%; p = 0.007) group and non-DM group (13.9% decrease; p = 0.021) at 12-week follow-up.

The accumulated research output warrants the initiation of a prospective study involving a larger patient cohort to evaluate the effect of mirabegron on male sexual function in addition to alleviate OAB symptoms. The objective of this study is to evaluate and compare the therapeutic effects on OAB symptoms, and sexual functions, in terms of erectile function and ejaculatory function, in sexually active OAB male treated with behavior therapy or behavior therapy plus Mirabegron (50 mg).

Conditions

Urinary Bladder, Overactive; Sexual Behavior; Sexual Activity; Behavior Therapy; Sexual Function Disturbances

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Behavior therapy alone

Behavior therapy alone

Group Type: ACTIVE_COMPARATOR

Behavior therapy alone

Intervention Type: BEHAVIORAL

1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;

2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;

3. use of relaxed and double-voiding techniques;

4. urethral milking to prevent post-micturition dribble;

5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;

6. bladder retraining that encourages men to hold on when they have sensory urgency;

7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);

8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;

9. treatment of constipation.

Behavior therapy plus mirabegron 50mg

Behavior therapy plus Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO

Group Type: EXPERIMENTAL

Behavior therapy alone

Intervention Type: BEHAVIORAL

1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;

2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;

3. use of relaxed and double-voiding techniques;

4. urethral milking to prevent post-micturition dribble;

5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;

6. bladder retraining that encourages men to hold on when they have sensory urgency;

7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);

8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;

9. treatment of constipation.

Mirabegron 50 MG Extended Release Oral Tablet

Intervention Type: DRUG

Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO

Interventions

Behavior therapy alone

1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;

2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;

3. use of relaxed and double-voiding techniques;

4. urethral milking to prevent post-micturition dribble;

5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;

6. bladder retraining that encourages men to hold on when they have sensory urgency;

7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);

8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;

9. treatment of constipation.

Intervention Type: BEHAVIORAL

Mirabegron 50 MG Extended Release Oral Tablet

Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO

Intervention Type: DRUG

Other Intervention Names

Mirabegron 50 MG

Eligibility Criteria

Inclusion Criteria

• Sexually active men with OAB ≥ 20 years
• Diagnosed with OAB based on OABSS (OABSS urgency score of ≥2 and sum score of ≥3)
• Patients can sign informed consent and record voiding diary

Exclusion Criteria

• Concurrent use of PDE5 inhibitor or testosterone therapy during study period
• History of stress urinary incontinence
• Neurologic conditions associated with OAB symptoms
• Evidence of active urinary tract infection or urinary tract stone at screening
• Confirmed or suspected genitourinary tract or pelvic malignancy
• Genitourinary tract operation during the 3-month period prior to baseline
• Postvoid residual urine volume (PVR) ≥ 100 mL
• History of uncontrolled hypertension (systolic >180 mmHg and/or diastolic >110 mmHg)
• History of intolerance to mirabegron
• History of medical conditions or presence of patient factors that, in the judgement of the investigator, would preclude adherence to study protocol
• Patient had received intravesical onabotulinumoxinA treatment within recent 6 months

• Minimum Eligible Age: 20 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Chang Gung Memorial Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tsang-Tang Hsieh, MD

Role: STUDY_CHAIR

Institutional Review Board Chang Gung Medical Foundation

Locations

Chang Gung Memorial Hospital, Chang Gung University College of Medicine

Kaohsiung City, , Taiwan

Countries

Taiwan

References

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. No abstract available.

Reference Type: BACKGROUND

PMID: 11857671 (View on PubMed)

Chuang YC, Liu SP, Lee KS, Liao L, Wang J, Yoo TK, Chu R, Sumarsono B. Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019 Jan;11(1):48-55. doi: 10.1111/luts.12193. Epub 2017 Oct 2.

Reference Type: BACKGROUND

PMID: 28967230 (View on PubMed)

Irwin DE, Milsom I, Reilly K, Hunskaar S, Kopp Z, Herschorn S, Coyne KS, Kelleher CJ, Artibani W, Abrams P. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008 Dec;5(12):2904-10. doi: 10.1111/j.1743-6109.2008.01000.x.

Reference Type: BACKGROUND

PMID: 19090944 (View on PubMed)

Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011 Jun;8(6):1603-15. doi: 10.1111/j.1743-6109.2011.02250.x. Epub 2011 Apr 14.

Reference Type: BACKGROUND

PMID: 21492396 (View on PubMed)

Yamaguchi O, Chapple CR. Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn. 2007;26(6):752-6. doi: 10.1002/nau.20420.

Reference Type: BACKGROUND

PMID: 17600372 (View on PubMed)

Cirino G, Sorrentino R, di Villa Bianca Rd, Popolo A, Palmieri A, Imbimbo C, Fusco F, Longo N, Tajana G, Ignarro LJ, Mirone V. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5531-6. doi: 10.1073/pnas.0931347100. Epub 2003 Apr 21.

Reference Type: BACKGROUND

PMID: 12707413 (View on PubMed)

Gur S, Peak T, Yafi FA, Kadowitz PJ, Sikka SC, Hellstrom WJ. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction? BJU Int. 2016 Sep;118(3):464-74. doi: 10.1111/bju.13515. Epub 2016 May 26.

Reference Type: BACKGROUND

PMID: 27124860 (View on PubMed)

Yilmaz-Oral D, Kaya-Sezginer E, Askin D, Hamurtekin Y, Gur S. Mirabegron, A Selective beta3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats. Exp Clin Endocrinol Diabetes. 2021 Mar;129(4):296-302. doi: 10.1055/a-0869-7493. Epub 2019 Apr 12.

Reference Type: BACKGROUND

PMID: 30978726 (View on PubMed)

Wu TH, Shen YC, Lee WC, Wang HJ, Chuang YC. Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. J Chin Med Assoc. 2020 Jan;83(1):55-59. doi: 10.1097/JCMA.0000000000000208.

Reference Type: BACKGROUND

PMID: 31567878 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

Management of Non-neurogenic Male LUTS. European Association of Urology, 2019 Guidelines

https://clinicaltrials.gov/ct2/show/NCT02916693?term=NCT02916693&draw=2&rank=1

ClinicalTrials.gov Identifier NCT02916693, Mirabegron For Erectile Dysfunction

Other Identifiers

202000790A3

Identifier Type: -

Identifier Source: org_study_id